|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's range||502.91 - 511.71|
|52-week range||462.61 - 832.70|
|Beta (5Y monthly)||0.92|
|PE ratio (TTM)||N/A|
|Earnings date||27 Jul 2022 - 01 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||711.67|
Investors are optimistic about Bio-Rad's (BIO) strong growth in its key product lines across several geographies.
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect improvement at the Animal Health segment.
Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.